Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733642 · ClinicalTrials.gov registry record · Phase 1
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00733642 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT00733642, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.
Interventions
- BIOLOGICAL PF-04360365 1 mg/kg
- BIOLOGICAL PF-04360365 3 mg/kg
- BIOLOGICAL PF-04360365 5 mg/kg
- BIOLOGICAL PF-04360365 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733642
The ClinicalTrials.gov registry entry for NCT00733642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-04360365 1 mg/kg is the first listed.
NCT00733642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733642 about?
NCT00733642 is a clinical study titled "Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease". The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.
What is the current status of trial NCT00733642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-08. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00733642?
The interventions under investigation include: PF-04360365 1 mg/kg (BIOLOGICAL), PF-04360365 3 mg/kg (BIOLOGICAL), PF-04360365 5 mg/kg (BIOLOGICAL), PF-04360365 10 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00733642?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.